论文部分内容阅读
近些年的临床研究表明，HIV-1会对美国FDA批准的抗HIV药物产生抗药性，影响治疗的效果。与其他病毒相比，HIV-1容易产生抗药性是由于它高速复制和RNA基因组逆转录为DNA时的易错性所致。HIV的抗药性可在体外用基因型和表现型检测法来确认。患者的药物假期往往是产生抗药毒株的直接原因。坚持用药，监测抗药毒株，多药联合治疗和不断研制新药是对付抗药性的主要手段。
In recent years, clinical studies have shown that HIV-1 will be resistant to the FDA-approved anti-HIV drugs and affect the efficacy of the treatment. HIV-1 is more susceptible to drug resistance than other viruses due to its high-speed replication and the error-prone nature of reverse transcription of the RNA genome into DNA. HIV resistance can be confirmed in vitro by genotypic and phenotypic assays. Patient’s drug holidays are often the direct cause of drug-resistant strains. Adhere to medication, monitoring drug-resistant strains, multi-drug combination therapy and the continuous development of new drugs is the main means to deal with drug resistance.